Vascular endothelial growth factor (VEGF) inhibitorsin cancer therapy: an update

References

• Dor Y, Keshet E. Ischemia-driven angiogenesis. Trends Cardiovas Med. 1997;7:289–294.
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, et al. Vascular Endothelial cell growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843–845.
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E Selective ablation of immature blood vessels in estab-lished human tumors flows vascular endothelial growth
   Google Scholar
• McMahon G. VEGF receptor signaling in tumor angio-genesis. The Oncologist 2000;5(1):3–10.
   Google Scholar
• Klagsburn M, D–Amore PA. vascular endothelial growth factor and its receptors. Cytokine Growth factor Rev. 1996;7:259–270.
   PubMedGoogle Scholar
• Ferrar N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.
   Google Scholar
• Miller KD, Sweeney CJ, Sledge GW Jr. Redegining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195–1206.
   Google Scholar
• Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(1):2–10.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Brown LF, Detmar M, et al. Vascular per-meability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029–1039.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435–439.
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin L, Tumorigenesis and the angiogenic switch, Nature 2003;3(6):401–410.
   Google Scholar
• Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, Ledda F, Ziche M, Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activa-tion in postcapillary endothelium. J Biol Chem 1998;273; 4220–4226.
   PubMed Web of Science ®Google Scholar
• Safran M, Kaelin Jr WJ. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111:779–783.
   PubMed Web of Science ®Google Scholar
• Motzer R, Rini BI, Michaelson MD, et al. SU11248, a novel tyrosine kinase inhibitor, shows antitumor acti-vity in second line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Proc Am Soc Clin Oncol. 2004; 22(14S):4500 (abstract 4500).
   Google Scholar
• Inai T, Mancusov M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestration, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35–52.
   PubMed Web of Science ®Google Scholar
• Rini BI, Small EJ. Biology and clinical development of vascular endothelial therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028–1043.
   PubMed Web of Science ®Google Scholar
• Heymach JV, Dong RP, Dimery I, et al. ZD6474, A novel antiangiogenic agent in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. Proc Am Soc Clin Oncol 2004; 22(14S);3051 (abstract 3051).
   Google Scholar
• Zhang W, Ran S, Sambade M, et al. A monoclonal antibody that blocks VEGF finding to VEGFR2 (KDR/ Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 2002;5:35–44.
   PubMedGoogle Scholar
• Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996;7:259–270.
   PubMedGoogle Scholar
• Weng DE, Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr Oncol Rep 2001;3:604–611.
   Google Scholar
• Dupont J, Schwartz L, Koutcher J, et al. Phase I and pharmacokinetic study of VEGF Trap administered subcu-taneously to patients with advanced solid malignancies. Proc ASCO 2004;22(14S):3009 (abstract 3009).
   Google Scholar
• Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003 Oct;30(5 Suppl 16):117–124.
   Google Scholar
• Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxcl/bevacizumab for metastatic breast cancer. San Antonio Breast Cancer Symposium, December 2005.
   Google Scholar
• Miller KD, Chap LI, Holmes FA, ct al. Randomized Phase II trial of capectabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23(4):792–799.
   PubMed Web of Science ®Google Scholar
• Spigel D, Kindsvogel K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. San Antonio Breast Cancer Symposium, December 2005.
   Google Scholar
• Miller KD, Burstein J, Elias AD, et al. Phase II study of SU11248, a multitargctcd receptor tyrosine kinase inhibitor in patients with previously treated metastatic breast cancer. 2005 ASCO Annual Meeting, Abstract 563.
   Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/lcucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer ] Clin Oncol 2O03;l(21): 60–65.
   Google Scholar
• Kabbinavar F, Schulz ], McClcod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23(16):3697–3705.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotccan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl ] Med 2004;350: 2335–2342.
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hamblcton ], Mass R, ct al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/lcucovorin improves survival for patients with metastatic colorectal cancer. ] Clin Oncol 2005;23(16): 3697–3705.
   Google Scholar
• Mitchell EP, Alberts SR, Schwarts MA, ct al. Tine addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer: an updated interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E32O0. Paper presented at: Gastrointestinal Cancers Symposium: Current Status and Future Directions for Prevention and Management; January 22–24, 2005; San Francisco, CA. Abstract 241.
   Google Scholar
• Saltz LB, Lcnz H, Hochester S. Randomized phase II trial of cctuximab, bevacizumab, irinotecan versus cetuximab and bevacizumab in irinotecan refractory colorectal cancer: interim report. Presented at the 2005 Gastrointestinal Cancers Symposium, Abstract 169b.
   Google Scholar
• Hecht JR. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-tluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Presented at 2005 ASCO Annual Meeting.
   Google Scholar
• Eisen T, Ahmad M, Gore E, et al. Phase I trial of BAY 43–9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. Paper presented at 2005 ASCO annual meeting, Abstract 7508.
   Google Scholar
• Johnson D, Fehrenbacher L, Novotny W, et al. Rando-mized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or meta-static non-small cell lung cancer. J Clin Oncol 2004; 22(1 ):2184–2191.
   Google Scholar
• Mesiano S, Ferrara N, Jaffe R. Role of Vascular endothelial growth factor in ovarian cancer. Am J Pathol 1998;154:1249–1256.
   Google Scholar
• Burger RA, Phase II trial of bevacizumab persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer; A Gynecology oncology group study. 2005 ASCO Annual meeting.
   Google Scholar
• Garcia AA, Oza AM, Hirte H, et al. Interim report of a phase II clinical trial of bevacizumab and low dose metro-nomic oral cyclophosphamide in recurrent ovarian and primary peritoneal carcinoma: A California Cancer Con-sortium Trial. 2005 ASCO Annual Meeting, Abstract 5000.
   Google Scholar
• Spigel DR, Hainsworth JD, Sosman A, et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma: update of a phase II multicenter trial. Abstract 4540 of the Annual 2005 American Society of Clinical Oncology Meeting.
   Google Scholar
• Hainsworth JD, Sosman A, Spigel DR, Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: a Minne Pearl Cancer Research Network phase I/II trial. Abstract 4542 of the 2005 Annual ASCO meeting.
   Google Scholar
• Escudier B, Szczylik T, Eisen W. Randomized phase II trial of the Rd kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma. Abstract 4510 of the 2005 Annual ASCO meeting.
   Google Scholar
• Ratain MJ, Eisen T, Stadler WM, et al. Final finding from a phase II, placebo-controlled randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma. Abstract 4544 of the 2005 Annual ASCO meeting.
   Google Scholar
• Motzer RJ, Rini BI, Michaelson BG, et al. Phase II trials of SU11248 show antitumor activity in second line therapy for patients with metastatic renal cell carcinoma. Abstract 4508 of the 2005 Annual ASCO meeting.
   Google Scholar